Zynerba: Gains on positive data from development disorder treatment study

Zynerba Pharmaceuticals

27/05/2020 12:27

** Shares of drug developer  ZYNE.O  rise 11.4% to $6.90
premarket
    ** Co reports positive data from mid-stage trial assessing
Zygel (ZYN002) along with standard-of-care for treatment of
behavioral symptoms associated with autism spectrum disorder in
pediatric and adolescent patients  urn:newsml:reuters.com:*:nGNX5BPvsr
    ** Patients showed both statistically significant and
clinically meaningful improvements at 14 weeks of treatment from
baseline - ZYNE
    ** Autism spectrum disorder is a developmental disorder that
affects communication and behavior; it affects approx. 1 mln
pediatric and adolescent patients between 5 and 17 years of age
in U.S.
    ** Stock rose 2.4% this year, up to last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))